Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
Date | Form | Description | XBRL | Pages | |
---|---|---|---|---|---|
10/15/25 | 4 | Statement of changes in beneficial ownership of securities |
![]() |
1 | |
10/15/25 | 3 | Initial statement of beneficial ownership of securities |
![]() |
4 | |
10/09/25 | 8-K | Current report |
![]() |
![]() ![]() |
58 |
09/03/25 | 8-K | Current report |
![]() |
![]() ![]() |
45 |
08/15/25 | EFFECT | Notice of Effectiveness |
![]() |
1 | |
08/14/25 | SCHEDULE 13G | Statement of Beneficial Ownership by Certain Investors |
![]() |
6 | |
08/14/25 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
![]() |
4 | |
08/14/25 | SCHEDULE 13G | Statement of Beneficial Ownership by Certain Investors |
![]() |
5 | |
08/13/25 | CORRESP | Correspondence |
![]() |
2 | |
08/13/25 | UPLOAD | SEC-generated letter |
![]() |
1 |